Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib + Topotecan in SCLC
NCT03227016Phase 1Unknown
- Sponsor
- Central European Society for Anticancer Drug Research
- Start
- Oct 2016
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of veliparib in small cell lung cancer (SCLC), sponsored by Central European Society for Anticancer Drug Research. Primary endpoint: Adverse Events at 6 months. Status: unknown.
02
Drugs
veliparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03227016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03227016.